BACKGROUND: Numerous novel genes have been identified in urothelial bladder cancer (UBC); genes including ninjurin, synuclein and neuropilin seem to be associated with invasive tumours and aggressive behaviour. AIMS: To define the protein expression of these biomarkers and to reveal their prognostic value in a large series of superficial (pTa) and minimally invasive (pT1) cases of UBC with a long and adequate follow-up. METHODS: Tissue microarray was done on 183 paraffin-embedded tumour tissues (pTa 81, pT1 102). Statistical analysis was performed to define the association between each of these biomarkers, clinical data and tumour outcomes. RESULTS: There was a statistically significant association between synuclein expression and tumour st...
We aimed to discover prognostic factors of muscle-invasive bladder cancer (MIBC) and investigate the...
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recur...
BACKGROUND:The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial ca...
BACKGROUND: Numerous novel genes have been identified in urothelial bladder cancer (UBC); genes incl...
Source of support: Departmental sources Background: Previous studies have shown that the expression ...
Background. Neurovascular-related genes have been implicated in the development of cancer. Studies h...
UnrestrictedUrothelial carcinoma of the urinary bladder is the seventh most common type of cancer wo...
Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant. Molecular subtyping studies ...
Objective: To identify candidate biomarkers correlated with clinical prognosis of patients with blad...
Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast hetero...
PURPOSE: To evaluate altered protein expression with tissue microarray methodology for 15 different ...
Background. Though there are several prognostic models, there is no protein-related prognostic model...
Urothelial bladder carcinoma (UBC) is an intricate malignancy with a variable natural history and cl...
Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bl...
Bladder cancer is a very common malignancy. Although new treatment strategies have been developed, t...
We aimed to discover prognostic factors of muscle-invasive bladder cancer (MIBC) and investigate the...
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recur...
BACKGROUND:The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial ca...
BACKGROUND: Numerous novel genes have been identified in urothelial bladder cancer (UBC); genes incl...
Source of support: Departmental sources Background: Previous studies have shown that the expression ...
Background. Neurovascular-related genes have been implicated in the development of cancer. Studies h...
UnrestrictedUrothelial carcinoma of the urinary bladder is the seventh most common type of cancer wo...
Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant. Molecular subtyping studies ...
Objective: To identify candidate biomarkers correlated with clinical prognosis of patients with blad...
Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast hetero...
PURPOSE: To evaluate altered protein expression with tissue microarray methodology for 15 different ...
Background. Though there are several prognostic models, there is no protein-related prognostic model...
Urothelial bladder carcinoma (UBC) is an intricate malignancy with a variable natural history and cl...
Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bl...
Bladder cancer is a very common malignancy. Although new treatment strategies have been developed, t...
We aimed to discover prognostic factors of muscle-invasive bladder cancer (MIBC) and investigate the...
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recur...
BACKGROUND:The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial ca...